Micrus Endovascular Launches Presidio Microcoil to Treat Large, Irregular Cerebral Aneurysms.

SUNNYVALE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced the worldwide market launch of its Presidio(TM) Microcoil product line for the treatment of large cerebral aneurysms. The Presidio Microcoil is a single, stretch resistant microcoil designed to deliver stable, predictable aneurysm framing and to increase coverage of the aneurysm wall and neck with a single coil deployment. The Presidio Microcoil incorporates a bioactive filament that independent researchers suggest may accelerate the healing process. These findings were presented in October of this year at the 8th Congress of the World Federation of Interventional and Therapeutic Neuroradiology.

"The Presidio Microcoil increases my clinical options," said Felipe Albuquerque, M.D., Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix. "The Presidio's anatomical compliance and unique loop design create a stable frame inside the aneurysm. Its additional length provides greater volume fill for increased packing density, as well as improved neck coverage."

"We view the Presidio Microcoil as a new dimension in framing, and we believe its addition to our flagship MicruSphere(R) framing coil brand will help us to further strengthen Micrus Endovascular's position as a market leader in the coiling business," said John Kilcoyne, Micrus Endovascular president and CEO. "This product provides a new tool to neurointerventionalists that allows for the rapid framing and filling of a wide range of complex aneurysms. Importantly, the Presidio Microcoil is a stretch resistant, Cerecyte(R) Coil, developed to provide the same handling and detachment performance that our customers have come to expect from our coils.

"Innovative and value-added product introductions are key to our growth strategy," Mr. Kilcoyne added. "Over the coming months we intend to aggressively expand our product portfolio."

About Micrus Endovascular Corporation

Micrus Endovascular develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists and neurosurgeons primarily to treat cerebral aneurysms responsible for hemorrhagic stroke, a significant cause of death in the United States. The Micrus product line enables physicians to gain access to the brain in a minimally invasive manner through the vessels of the circulatory system. Micrus' proprietary, three-dimensional microcoils are unique in that they automatically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells accessory devices and products used in conjunction with its microcoils.

Forward-Looking Statements

Micrus, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the Company's dependence upon the increased adoption of embolic coiling as a procedure to treat cerebral aneurysms, the Company's limited operating history and history of significant operating losses, the Company's involvement in patent litigation with Boston Scientific Corporation, fluctuations in quarterly operating results which are difficult to predict, the Company's dependence on developing new products or product enhancements, challenges associated with rapid growth, challenges associated with complying with applicable state, federal and international regulations related to sales of medical devices and governing our relationships with physicians and other consultants, the Company's ability to compete with large, well-established medical device manufacturers with significant resources, the Company's dependence on obtaining timely U.S. Food and Drug Administration (FDA) as well as applicable international regulatory clearances and approvals for our future products or product enhancements, and other risks as detailed from time-to-time in the Company's final prospectus dated June 16, 2005 and reports and filings with the Securities and Exchange Commission under the Securities and Exchange Act of 1934. All forward-looking statements in this release represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update forward-looking statements.